Pricing Log in Create free account
Saturday 7 November 2026 Export ARCT’s income statement to Excel — free account

Arcturus Therapeutics Holdings Inc.

ARCT Healthcare Biotechnology

Arcturus Therapeutics Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $82.0 million, down 46.1% from fiscal 2024.

Revenue
+6.68%
EPS
+46.9%
Free cash flow
+59.9%

Quarter to September 2026, against a year earlier

10.30 0.94 +10.04%
Market cap
$266.0M
P/E
0.0×
Fwd P/E
−3.0×
Dividend yield
—
F-score
2/9
Altman Z
−0.61
Beneish M
−1.29
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 8.40%

Capital & Financial Ratios $m

Size
Market Cap 266.04
Revenue ttm 30.51
Net income ttm (87.24)
Free cash flow ttm (62.39)
Net debt Q (184.82)
Valuation
P/E 0.00
Forward P/E (3.02) (negative: loss-making)
Price / sales 9.60
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.74
Financial health
Current ratio Q 6.68 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 14.04
Growth
Revenue growth Q +6.68% (above 0%: growing)
Operating income growth Q +44.37% (above 0%: growing)
EPS, this year −40.02% (below 0%: weak)
EPS, next year A −11.23% (below 0%: weak)
Revenue, next year A −77.34% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −13.50% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 6.0×, against a ten-year median of 3.2×; over the ten years it ranged from 0.2× in 2025 to 177× in 2020.
P/S against its own 10 years 68.35%
10-year low 10-year high
P/B against its own 10 years 28.37%
10-year low 10-year high
EV/Sales against its own 10 years 69.55%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 347 292 231 185
Receivables 32 4 6 1
Inventory — — — —
Other — — — —
387 306 241 189
2023 2024 2025 Q'26
Payables 5 7 4 6
ST’ Debt — — — —
Other — — — —
82 65 36 28

Compound Annual Growth %

10y 5y 3y
Sales — 53.78% (26.43%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 11.93% (11.61%) (7.49%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.60 Actual −0.26

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.92 −1.03 Miss by 0.11
Q1 FY26 −1.14 −0.95 Beat by 0.19
Q2 FY26 −1.07 −0.84 Beat by 0.23
Q3 FY26 −0.60 −0.26 Beat by 0.34
Q4 FY26 −1.01 — Reports 2 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.95) (0.84) (0.26) — —
’25 (0.52) (0.34) (0.49) (1.03) (2.40)
’24 (1.00) (0.64) (0.26) (1.11) (3.00)
’23 1.87 (1.98) (0.61) (0.40) (1.12)
’22 (1.94) (0.82) (1.33) 4.33 0.35
’21 (2.15) (2.07) (2.05) (1.47) (7.74)
’20 (0.67) (0.55) (0.92) (1.25) (3.55)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 2 3 18 — —
’25 29 28 17 7 82
’24 38 50 42 23 152
’23 80 11 45 31 167
’22 5 27 13 160 206
’21 2 2 2 6 12
’20 3 2 2 2 10
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (19) (20) (7) — —
’25 (35) (6) (17) (16) (74)
’24 (6) (30) (24) 0 (60)
’23 (36) 51 (32) (1) (18)
’22 (49) (37) (42) 160 32
’21 (43) (33) (17) (42) (135)
’20 (12) (8) (16) (7) (43)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (19) (20) (7) — —
’25 (35) (6) (17) (16) (75)
’24 (6) (30) (24) 0 (60)
’23 (37) 50 (33) (2) (21)
’22 (51) (36) (45) 156 24
’21 (43) (33) (18) (44) (138)
’20 (12) (9) (16) (7) (45)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 20 13 16 21 10 12 206 167 152 82 31 +16.7% 19 29 42 (20.0%)
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 0.0 pt
EBT (2) (11) (22) (26) (72) (204) 11 (28) (81) (66) (87) +51.8%
EBT margin, % (7.54) (83.87) (138.29) (125.02) (756.35) (1,647.98) 5.17 (16.72) (53.14) (80.19) (285.92) (72.6) pt
Net income (2) (11) (22) (26) (72) (204) 9 (30) (81) (66) (87) +51.4%
Per share, $
Per share, $ Revenue 10.03 4.21 1.56 1.72 0.47 0.47 7.79 6.26 5.64 3.00 1.07 (12.6%)
Earnings (0.77) (3.53) (2.16) (2.15) (3.55) (7.74) 0.35 (1.12) (3.00) (2.40) (3.08) +13.4%
Cash flow (1.41) (0.15) (2.06) (0.53) (2.11) (5.13) 1.21 (0.68) (2.21) (2.71) (2.20) +7.6%
Capex (0.34) (0.07) (0.15) (0.07) (0.09) (0.13) (0.29) (0.11) (0.02) (0.01) 0.00 (33.7%)
Free cash flow (1.75) (0.22) (2.21) (0.60) (2.20) (5.26) 0.92 (0.79) (2.24) (2.72) (2.19) +5.0%
Book value 0.78 10.95 1.35 2.14 19.53 8.67 10.22 10.46 8.93 7.81 5.93 +29.3%
Shares, m 2 3 10 12 20 26 26 27 27 27 28 +33.5%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 49.12 0.00 0.00 0.00 0.00 4.9
P/S 0.00 0.00 2.90 6.31 92.34 78.81 2.14 5.28 3.01 2.05 9.60 19.3
P/B 19.93 0.73 3.34 5.09 2.22 4.27 1.63 3.16 1.90 0.78 1.74 4.3
EV/Sales 0.00 0.00 1.20 3.61 45.40 53.94 0.68 3.69 1.62 0.15 6.02 11.0
EV/FCF (6.54) 35.10 (0.85) (10.32) (9.71) (4.81) 5.79 (29.27) (4.09) (0.17) (2.95) (2.5)
Cash, $m
Cash, $m Operating cash flow (3) 0 (21) (6) (43) (135) 32 (18) (60) (74) (62) +43.6%
Capex (1) 0 (1) (1) (2) (3) (8) (3) (1) 0 0 (11.5%)
Free cash flow (4) (1) (22) (7) (45) (138) 24 (21) (60) (75) (62) +40.2%
Balance, $m
Balance, $m Working capital 4 40 29 53 418 279 276 305 240 205 161 +56.7%
Net debt (8) (49) (27) (56) (448) (307) (331) (347) (292) (231) (185) +44.9%
Shareholders’ equity 2 34 14 26 397 228 270 279 241 214 169 +72.6%
Returns, %
Returns, % ROA (3.68) (33.16) (45.28) (41.14) (25.83) (46.86) 2.22 (6.76) (20.93) (21.39) (35.06) (17.7) pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (4.43) (61.64) (91.85) (131.82) (34.17) (65.20) 3.75 (10.83) (31.16) (28.92) (44.37) (24.5) pt
People
People Employees 19 60 72 88 118 177 170 180 176 111 — +21.7%
Revenue/emp, $m 1.07 0.22 0.22 0.24 0.08 0.07 1.21 0.93 0.87 0.74 — (4.1%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Arcturus Therapeutics Holdings Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NAUT Nautilus Biotechnology, Inc. $273.9M — (loss-making) — — n/m −28.59% (below 0%: shrinking) 89.74% (7,152.56%) Compare
IPSC Century Therapeutics, Inc. $273.4M — (loss-making) — (loss-making) +12,667.72% (above 0%: growing) n/m +26.66% (above 0%: growing) 100.00% 0.00% Compare
TTRX Turn Therapeutics Inc. $273.0M — (loss-making) — — n/m −74.76% (below 0%: shrinking) — 0.00% Compare
VOGX Vogenx Inc $270.8M — — — n/m — — 0.00% Compare
SABS SAB Biotherapeutics, Inc. $267.5M — (loss-making) 19.9× −90.95% (below 0%: shrinking) n/m −59.75% (below 0%: shrinking) 100.00% 0.00% Compare
RCKT Rocket Pharmaceuticals, Inc. $267.3M — (loss-making) — — n/m +19.16% (above 0%: growing) 0.00% 0.00% Compare
ARCT Arcturus Therapeutics Holdings Inc. $266.0M — (loss-making) — (loss-making) +6.68% (above 0%: growing) n/m +59.86% (above 0%: growing) 100.00% (50.20%)
SPRY ARS Pharmaceuticals, Inc. $263.5M — (loss-making) — (loss-making) +16.03% (above 0%: growing) n/m +36.52% (above 0%: growing) 0.00% (90.62%) Compare
QTTB Q32 Bio Inc. $263.5M 3.1× — (loss-making) −1,928.18% (below 0%: shrinking) n/m +71.13% (above 0%: growing) 100.00% 0.00% Compare
Median of peers $269.2M — — −37.46% — +19.16% 94.87% 0.00%

All 621 Biotechnology stocks →

Arcturus Therapeutics Holdings Inc. (ARCT) Latest News

5 Nov

Impact 3 · · MarketBeat transcript
Impact 3 · · Business Wire

26 Oct

Impact 3 · · Business Wire

24 Sep

Impact 4 · · MarketBeat

23 Sep

Impact 4 · · Business Wire

18 Sep

Impact 4 ·

11 Aug

Impact 4 · · MarketBeat

6 Aug

Impact 4 ·
Impact 3 · · MarketBeat transcript
Impact 3 ·

2 Jul

Impact 4 ·

5 Jun

Impact 3 · · MarketBeat

8 May

Impact 4 · · Moby

7 May

Impact 3 · · MarketBeat
Impact 3 · · Business Wire

23 Mar

Impact 4 · · MarketBeat

12 Mar

Impact 4 · · MarketBeat

4 Mar

Impact 4 · · Moby
Impact 4 · · GuruFocus.com

3 Mar

Impact 4 · · MarketBeat
Impact 4 · · Business Wire

16 Feb

Impact 3 · · Simply Wall St.

11 Feb

Impact 4 · · MarketBeat

2 Feb

Impact 4 · · Insider Monkey

13 Jan

Impact 3 ·

12 Jan

Impact 4 · · MarketBeat
Impact 4 · · Simply Wall St.BarchartMT NewswiresSimply Wall St.Simply Wall St.Simply Wall St.

10 Jan

Impact 4 · · Barchart

8 Jan

Impact 3 · · Business Wire

9 Dec

Impact 3 · · GuruFocus.com
stockrow.com/ARCT · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com